Abstract:Background Epigenetic alternation is a common contributing factor to neoplastic transformation. Although previous studies have reported a cluster of aberrant promoter methylation changes associated with silencing of tumor suppressor genes, little is known concerning their sequential DNA methylation changes during the carcinogenetic process. The aim of the present study was to address a genome-wide search for identifying potentially important methylated changes and investigate the onset and pattern of methylation changes during the progression of colorectal neoplasia. Methods A three-phase design was employed in this study. In the screening phase, DNA methylation profile of 12 pairs of colorectal cancer (CRC) and adjacent normal tissues was analyzed by using the Illumina MethylationEPIC BeadChip. Significant CpG sites were selected based on a cross-validation analysis from The Cancer Genome Atlas (TCGA) database. Methylation levels of candidate CpGs were assessed using pyrosequencing in the training dataset (tumor lesions and adjacent normal tissues from 46 CRCs) and the validation dataset (tumor lesions and paired normal tissues from 13 hyperplastic polyps, 129 adenomas, and 256 CRCs). A linear mixed-effects model was used to examine the incremental changes of DNA methylation during the progression of colorectal neoplasia. Results The comparisons between normal and tumor samples in the screening phase revealed an extensive CRC-specific methylomic pattern with 174,006 (21%) methylated CpG sites, of which 22,232 (13%) were hyermethylated and 151,774 (87%) were hypomethylated. Hypermethylation mostly occurred in CpG islands with an overlap of gene promoters, while hypomethylation tended to be mapped far away from functional regions. Further cross validation analysis from TCGA dataset confirmed 265 hypermethylated promoters coupling with downregulated gene expression. Among which, hypermethylated changes in MEEPD2 promoter was successfully replicated in both training and validation phase. Significant hypermethylation appeared since precursor lesions with an extensive modification in CRCs. The linear mixed-effects modeling analysis found that a cumulative pattern of MPPED2 methylation changes from normal mucosa to hyperplastic polyp to adenoma, and to carcinoma ( P < 0.001). Conclusions Our findings indicate that epigenetic alterations of MPPED2 promoter region appear sequentially during the colorectal neoplastic progression. It might be able to serve as a promising biomarker for early diagnosis and stage surveillance of colorectal tumorigenesis.

Methylated Promoters of Genes Encoding Protocadherins As a New Cancer Biomarker Family.

Epigenetic Silencing of Protocadherin 10 in Colorectal Cancer.

Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer

Circulating Methylated DNA As Biomarkers for Cancer Detection

Protocadherin-1 Serves As a Prognostic Biomarker and Promotes Pancreatic Cancer Progression by Suppressing CD8+ T Cell Infiltration Through CCL5-CCR5 Axis.

Protocadherin 17 Acts As a Tumour Suppressor Inducing Tumour Cell Apoptosis and Autophagy, and is Frequently Methylated in Gastric and Colorectal Cancers

Clinical Significance of Methylation of E-cadherin and P14arf Gene Promoters in Skin Squamous Cell Carcinoma Tissues.

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Hypermethylation of Protocadherin Γ Subfamily A12 and Solute Carrier Family 19 A 1 Promoters Contributes to the Occurrence and Metastasis of Colorectal Cancer

Methylation and Expression of Nonclustered Protocadherins Encoding Genes and Risk of Precancerous Gastric Lesions in a High-Risk Population

Methylation of Protocadherin 10, a Novel Tumor Suppressor, is Associated with Poor Prognosis in Patients with Gastric Cancer

Aberrant expression and functions of protocadherins in human malignant tumors

Methylomics and cancer: the current state of methylation profiling and marker development for clinical care

Identification of Transcription Factor/Gene Axis in Colon Cancer Using a Methylome Approach

Promoter-hypermethylation Associated Defective Expression of E-cadherin in Primary Non-Small Cell Lung Cancer.

Quantitative Assessment of Gene Promoter Methylation in Non-Small Cell Lung Cancer Using Methylation-Sensitive High-Resolution Melting.

Aberrant Promoter CpG Methylation and Its Translational Applications in Breast Cancer

Novel Methylation-Driven Genes Identified As Prognostic Indicators for Lung Squamous Cell Carcinoma

High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers.

Genome-wide DNA methylation profiling reveals a novel hypermethylated biomarker PRKCB in gastric cancer

Discovered Key CpG Sites by Analyzing DNA Methylation and Gene Expression in Breast Cancer Samples